Oxford BioMedica PLC, a leading gene and cell therapy company, represents values of innovation, collaboration, and scientific excellence. With a corporate philosophy focused on advancing transformative treatments, Oxford BioMedica is committed to improving the lives of patients worldwide. The company's dedication to pioneering research and development is evident in their exceptional product portfolio and collaborations with top-tier partners. Oxford BioMedica PLC strives to deliver cutting-edge therapies that address unmet medical needs, leveraging its expertise in lentiviral vector and high-quality manufacturing. As a result, Oxford BioMedica PLC continues to establish itself as a trusted name in the biopharmaceutical industry, driving advancements in gene and cell therapies.

Oxford BioMedica PLC is primarily present in the United Kingdom. With its headquarters in Oxford, the company operates within the region and has a strong base in the country. As a leading biopharmaceutical company, Oxford BioMedica PLC focuses on innovative gene and cell therapies, advancing the field of medicine. While the company's presence expands globally through collaborations and partnerships, its primary focus remains in the UK, contributing to the advancement of healthcare within the local market.

Oxford BioMedica PLC has achieved several significant milestones. The company has successfully developed and commercialized gene and cell therapies, making significant progress in the field of gene and cell therapy. Oxford BioMedica has achieved regulatory approvals for its innovative products, such as the approval of its CAR-T therapy called Kymriah™ by the U.S. Food and Drug Administration. Furthermore, the company has also established collaborations with major pharmaceutical companies, including Novartis and Sanofi, to further advance its gene and cell therapy platform. These achievements have solidified Oxford BioMedica PLC's position as a leader in the development of gene and cell therapies, driving innovation and creating value in the biopharmaceutical industry.

Oxford BioMedica PLC is a renowned biopharmaceutical company with a rich history and background. Established in 1995, the company specializes in gene and cell therapy research and development. With its headquarters in Oxford, United Kingdom, Oxford BioMedica has gained global recognition for its innovative therapies and collaborations with major pharmaceutical companies. The company has a strong track record in gene therapy manufacturing and has successfully brought multiple therapies to market. With its dedicated team of scientists and cutting-edge technologies, Oxford BioMedica continues to pave the way in advancing gene and cell therapy for the betterment of patients worldwide.

The main competitors of Oxford BioMedica PLC in the market include companies such as Novartis AG, Johnson & Johnson, and Bluebird Bio Inc.

Oxford BioMedica PLC is primarily active in the biotechnology and healthcare industries. As a leading gene and cell therapy company, Oxford BioMedica focuses on developing and commercializing innovative therapies for the treatment of serious diseases. Their expertise lies in the areas of lentiviral vector delivery systems and manufacturing processes, enabling the production of gene and cell therapies. With their cutting-edge technologies and partnerships with pharmaceutical companies, Oxford BioMedica is at the forefront of advancing medical solutions and improving patient outcomes in the biotechnology and healthcare sectors.

The business model of Oxford BioMedica PLC is focused on the development and commercialization of innovative gene and cell therapies. With a strong emphasis on lentiviral vectors, the company aims to transform the treatment of various diseases by delivering life-changing medicines to patients in need. Oxford BioMedica PLC collaborates with pharmaceutical partners, providing them with its proprietary LentiVector® platform to develop potential therapies. By leveraging its expertise in gene and cell therapy, Oxford BioMedica PLC is dedicated to advancing breakthrough treatments and improving healthcare outcomes for patients globally.

Το Oxford Biomedica P/E είναι -8,04.

Το KUV της εταιρείας Oxford Biomedica είναι 2,44.

Το AlleAktien Qualitätsscore για το Oxford Biomedica είναι 5/10.

Ο κύκλος εργασιών του αναμενόμενη Oxford Biomedica είναι 133,23 Εκ. GBP.

Το αναμενόμενη Oxford Biomedica κέρδος είναι -40,47 Εκ. GBP.

Oxford BioMedica PLC is an innovative biopharmaceutical company specializing in the development and manufacturing of gene therapy products. The company's business model focuses on licensed programs, proprietary programs, and services. Oxford BioMedica licenses its technology platform and manufacturing capabilities to leading biopharmaceutical companies for the development of customized gene therapies. The company also develops and markets its own gene therapy products, with a focus on treating rare diseases. Additionally, Oxford BioMedica offers contract research services along the entire value chain of gene therapy development. The company's main product is the LentiVector technology platform, which utilizes recombinant lentiviruses for efficient gene transfer. Oxford BioMedica is expanding its manufacturing capacity with new facilities in the United States.

Η Oxford Biomedica καταβάλλει μια διανομή της τάξεως των 0 GBP διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Oxford Biomedica αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Oxford Biomedica είναι GB00BDFBVT43.

Το WKN της Oxford Biomedica είναι A2JLRX.

Ο τίκερ της Oxford Biomedica είναι OXB.L.

Κατά τους τελευταίους 12 μήνες η Oxford Biomedica κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Oxford Biomedica προβλέπεται να πληρώσει μέρισμα 0 GBP.

Η απόδοση μερίσματος της Oxford Biomedica ανέρχεται σήμερα στο .

Oxford Biomedica πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Oxford Biomedica πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 GBP. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Oxford Biomedica ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Oxford Biomedica από την 30/8/2024 με τιμή 0 GBP, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 30/8/2024.

Η τελευταία μερίσματος έγινε στις 30/8/2024.

Το έτος 2023, η Oxford Biomedica διένειμε 0 GBP ως μερίσματα.

Τα μερίσματα του Oxford Biomedica καταβάλλονται σε GBP.